CELLBXHEALTH PLC - Preliminary results for the year ended 31 December 2025

CELLBXHEALTH PLC provided an investor update highlighting its strategic transformation into a commercially focused precision oncology company, leveraging its proprietary circulating tumour cell (CTC) technology platform to improve cancer diagnostics, patient monitoring, and drug development. The company reported significant operational restructuring, delivering more than £6.6 million in annualised cost savings, reducing headcount by over 60%, and establishing a clear pathway towards positive EBITDA by late 2028. Management expects revenue growth of approximately 50% in 2026, supported by a growing commercial pipeline and strategic partnerships with AstraZeneca, AdventHealth, and NHS-led clinical programmes. Operating in a rapidly expanding liquid biopsy market forecast to exceed $1.1 billion by 2031, CELLBXHEALTH is positioned to capitalise on increasing demand for advanced cancer testing solutions that complement traditional tissue biopsy and circulating tumour DNA analysis. The company’s platform is supported by over 250,000 processed samples, 120+ peer-reviewed publications, 102 installed instruments across 61 sites, and a robust intellectual property portfolio. Management highlighted multiple near-term growth catalysts, including biopharma collaborations, NHS lung cancer programme data, expanded laboratory services, and further commercial agreements. With £4.3 million of cash at the end of Q1 2026, improved gross margin targets, a streamlined cost base, and a focus on revenue-generating opportunities, CELLBXHEALTH remains focused on accelerating commercial adoption, expanding its market presence, and delivering long-term shareholder value.